These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1801 related articles for article (PubMed ID: 27338353)

  • 41. Etiology and pathogenesis of Parkinson's disease.
    Olanow CW; Tatton WG
    Annu Rev Neurosci; 1999; 22():123-44. PubMed ID: 10202534
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Anti-oxidant polydatin (piceid) protects against substantia nigral motor degeneration in multiple rodent models of Parkinson's disease.
    Chen Y; Zhang DQ; Liao Z; Wang B; Gong S; Wang C; Zhang MZ; Wang GH; Cai H; Liao FF; Xu JP
    Mol Neurodegener; 2015 Mar; 10():4. PubMed ID: 26013581
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Levodopa Therapy for Parkinson's Disease: History, Current Status and Perspectives.
    Bogetofte H; Alamyar A; Blaabjerg M; Meyer M
    CNS Neurol Disord Drug Targets; 2020; 19(8):572-583. PubMed ID: 32703142
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Signature of Aberrantly Expressed microRNAs in the Striatum of Rotenone-Induced Parkinsonian Rats.
    Horst CH; Schlemmer F; de Aguiar Montenegro N; Domingues ACM; Ferreira GG; da Silva Ribeiro CY; de Andrade RR; Del Bel Guimarães E; Titze-de-Almeida SS; Titze-de-Almeida R
    Neurochem Res; 2018 Nov; 43(11):2132-2140. PubMed ID: 30267378
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Neuroprotective Effects of Betulin in Pharmacological and Transgenic Caenorhabditis elegans Models of Parkinson's Disease.
    Tsai CW; Tsai RT; Liu SP; Chen CS; Tsai MC; Chien SH; Hung HS; Lin SZ; Shyu WC; Fu RH
    Cell Transplant; 2017 Dec; 26(12):1903-1918. PubMed ID: 29390878
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Neuroprotective effects of stemazole in the MPTP-induced acute model of Parkinson's disease: Involvement of the dopamine system.
    Guo Z; Xu S; Du N; Liu J; Huang Y; Han M
    Neurosci Lett; 2016 Mar; 616():152-9. PubMed ID: 26827716
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A Research Update on Exendin-4 as a Novel Molecule Against Parkinson's Disease.
    Singh NK; Singh A; Varshney M; Agrawal R
    Curr Mol Med; 2023; 23(9):889-900. PubMed ID: 37254536
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Neuroprotective potential of spermidine against rotenone induced Parkinson's disease in rats.
    Sharma S; Kumar P; Deshmukh R
    Neurochem Int; 2018 Jun; 116():104-111. PubMed ID: 29501454
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of caffeine in Parkinson's disease: from neuroprotection to the management of motor and non-motor symptoms.
    Prediger RD
    J Alzheimers Dis; 2010; 20 Suppl 1():S205-20. PubMed ID: 20182024
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Parkinson's disease a futile entangle of Mankind's credence on an herbal remedy: A review.
    Chang YM; Manoj Kumar M; Lu CY; Te Tsai C; Tsai CC; Liao PH; Lin SL; Chang CC; Mahalakshmi B; Kuo WW; Huang CY
    Life Sci; 2020 Sep; 257():118019. PubMed ID: 32629002
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Inhibition of HDAC6 activity protects dopaminergic neurons from alpha-synuclein toxicity.
    Francelle L; Outeiro TF; Rappold GA
    Sci Rep; 2020 Apr; 10(1):6064. PubMed ID: 32269243
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Determinants of dopaminergic neuron loss in Parkinson's disease.
    Surmeier DJ
    FEBS J; 2018 Oct; 285(19):3657-3668. PubMed ID: 30028088
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Initiation and propagation of α-synuclein aggregation in the nervous system.
    Hijaz BA; Volpicelli-Daley LA
    Mol Neurodegener; 2020 Mar; 15(1):19. PubMed ID: 32143659
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A zebrafish screen reveals Renin-angiotensin system inhibitors as neuroprotective via mitochondrial restoration in dopamine neurons.
    Kim GJ; Mo H; Liu H; Wu Z; Chen S; Zheng J; Zhao X; Nucum D; Shortland J; Peng L; Elepano M; Tang B; Olson S; Paras N; Li H; Renslo AR; Arkin MR; Huang B; Lu B; Sirota M; Guo S
    Elife; 2021 Sep; 10():. PubMed ID: 34550070
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Neuropathology of sporadic Parkinson disease before the appearance of parkinsonism: preclinical Parkinson disease.
    Ferrer I; Martinez A; Blanco R; Dalfó E; Carmona M
    J Neural Transm (Vienna); 2011 May; 118(5):821-39. PubMed ID: 20862500
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Biomarkers in Parkinson's disease (recent update).
    Sharma S; Moon CS; Khogali A; Haidous A; Chabenne A; Ojo C; Jelebinkov M; Kurdi Y; Ebadi M
    Neurochem Int; 2013 Sep; 63(3):201-29. PubMed ID: 23791710
    [TBL] [Abstract][Full Text] [Related]  

  • 57. AAV2-mediated striatum delivery of human CDNF prevents the deterioration of midbrain dopamine neurons in a 6-hydroxydopamine induced parkinsonian rat model.
    Ren X; Zhang T; Gong X; Hu G; Ding W; Wang X
    Exp Neurol; 2013 Oct; 248():148-56. PubMed ID: 23764500
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Intranasal insulin protects against substantia nigra dopaminergic neuronal loss and alleviates motor deficits induced by 6-OHDA in rats.
    Pang Y; Lin S; Wright C; Shen J; Carter K; Bhatt A; Fan LW
    Neuroscience; 2016 Mar; 318():157-65. PubMed ID: 26777890
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Natural Neuroprotective Compounds Used in the 6-Hydroxydopamine- Induced Parkinson's Disease in Zebrafish: The Current Applications and Perspectives.
    Abidar S; Hritcu L; Nhiri M
    CNS Neurol Disord Drug Targets; 2023; 22(10):1472-1483. PubMed ID: 36306449
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Understanding multifactorial architecture of Parkinson's disease: pathophysiology to management.
    Kaur R; Mehan S; Singh S
    Neurol Sci; 2019 Jan; 40(1):13-23. PubMed ID: 30267336
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 91.